Recordati licenses Pharmathen's drug delivery technology
This article was originally published in Scrip
The Greek firm Pharmathen has granted Recordatiexclusive rights to a drug delivery technology that it has developed. The technology is already being used in potential products that are nearing the market, Pharmathen reports. The company manufactures and markets generics, and had sales last year of €102 million. It also has six innovative and/or life cycle management projects in its R&D pipeline.